NL300415I2 - - Google Patents

Download PDF

Info

Publication number
NL300415I2
NL300415I2 NL300415C NL300415C NL300415I2 NL 300415 I2 NL300415 I2 NL 300415I2 NL 300415 C NL300415 C NL 300415C NL 300415 C NL300415 C NL 300415C NL 300415 I2 NL300415 I2 NL 300415I2
Authority
NL
Netherlands
Application number
NL300415C
Other languages
Dutch (nl)
Other versions
NL300415I1 (nl
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906437.0A external-priority patent/GB9906437D0/en
Priority claimed from GBGB9909077.1A external-priority patent/GB9909077D0/en
Priority claimed from GBGB9909466.6A external-priority patent/GB9909466D0/en
Priority claimed from GBGB9916677.9A external-priority patent/GB9916677D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of NL300415I1 publication Critical patent/NL300415I1/nl
Publication of NL300415I2 publication Critical patent/NL300415I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL300415C 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn NL300415I1 (nl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9906437.0A GB9906437D0 (en) 1999-03-19 1999-03-19 Vaccine
GBGB9909077.1A GB9909077D0 (en) 1999-04-20 1999-04-20 Novel compositions
GBGB9909466.6A GB9909466D0 (en) 1999-04-23 1999-04-23 Vaccines
GBGB9916677.9A GB9916677D0 (en) 1999-07-15 1999-07-15 Vaccine
PCT/EP2000/002468 WO2000056360A2 (en) 1999-03-19 2000-03-17 Vaccine against antigens from bacteriae

Publications (2)

Publication Number Publication Date
NL300415I1 NL300415I1 (nl) 2009-12-01
NL300415I2 true NL300415I2 (enExample) 2016-12-13

Family

ID=27451884

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300415C NL300415I1 (nl) 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn

Country Status (32)

Country Link
US (8) US20030147922A1 (enExample)
EP (6) EP1880735A3 (enExample)
JP (4) JP2002539273A (enExample)
KR (3) KR100642044B1 (enExample)
CN (3) CN1192798C (enExample)
AR (3) AR022965A1 (enExample)
AT (3) ATE387214T1 (enExample)
AU (3) AU750762B2 (enExample)
BE (1) BE1025464I2 (enExample)
BR (4) BR0009166A (enExample)
CA (3) CA2366152A1 (enExample)
CY (3) CY1107561T1 (enExample)
CZ (3) CZ301445B6 (enExample)
DE (4) DE60038166T2 (enExample)
DK (2) DK1162999T3 (enExample)
ES (3) ES2275499T3 (enExample)
FR (1) FR10C0008I2 (enExample)
HK (3) HK1043730A1 (enExample)
HU (4) HU229968B1 (enExample)
IL (5) IL145045A0 (enExample)
LU (1) LU91652I2 (enExample)
MX (1) MXPA01009452A (enExample)
MY (2) MY125387A (enExample)
NL (1) NL300415I1 (enExample)
NO (4) NO330736B1 (enExample)
NZ (3) NZ513840A (enExample)
PL (3) PL355178A1 (enExample)
PT (2) PT1163000E (enExample)
SI (2) SI1163000T1 (enExample)
TR (3) TR200102735T2 (enExample)
TW (3) TWI281403B (enExample)
WO (3) WO2000056360A2 (enExample)

Families Citing this family (289)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
DE69737413T2 (de) 1996-01-04 2007-10-31 Novartis Vaccines and Diagnostics, Inc., Emeryville Bakterioferritin aus helicobacter pylori
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US20010016200A1 (en) 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
ES2628744T3 (es) 1998-05-22 2017-08-03 Ottawa Hospital Research Institute MĆ©todos y productos para inducir inmunidad en mucosas
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
EP1880735A3 (en) * 1999-03-19 2008-03-12 GlaxoSmithKline Biologicals S.A. Vaccine
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CA2425303A1 (en) 2000-10-27 2002-05-02 John Telford Nucleic acids and proteins from streptococcus groups a & b
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
HRP20030598B1 (hr) 2001-01-23 2013-05-31 Aventis Pasteur Multivalentna meningokokalna polisaharidno-proteinska konjugirana vakcina
DK1361890T3 (da) 2001-02-23 2011-06-27 Glaxosmithkline Biolog Sa Influenzavaccineformuleringer til intradermal indgift
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0109297D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
ES2386386T3 (es) 2001-12-12 2012-08-20 Novartis Vaccines And Diagnostics S.R.L. InmunizaciĆ³n contra Chlamydia trachomatis
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
JP4646516B2 (ja) 2002-02-20 2011-03-09 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ 惐ć‚Æć‚·ćƒ³ć‚ŗ ć‚¢ćƒ³ćƒ‰ ćƒ€ć‚¤ć‚¢ć‚°ćƒŽć‚¹ćƒ†ć‚£ćƒƒć‚Æć‚¹ļ¼Œć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ćƒ¼ćƒ†ćƒƒćƒ‰ åøē€ć—ćŸćƒćƒŖćƒšćƒ—ćƒćƒ‰å«ęœ‰åˆ†å­ć‚’ęœ‰ć™ć‚‹å¾®ē²’子
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
BR0310042A (pt) * 2002-05-14 2005-04-05 Chiron Srl Vacinas de combinaĆ§Ć£o mucosal para meningite bacteriana
DE60328481D1 (de) * 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthƤlt
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
DK1549338T3 (da) 2002-10-11 2011-03-28 Novartis Vaccines & Diagnostic Polypeptidvacciner til bred beskyttelse mod hypervirulente meningokok-afstamningslinier
AU2003274011B2 (en) * 2002-10-15 2010-03-04 Intercell Ag Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
KR101130948B1 (ko) 2002-11-01 2012-03-30 źø€ė½ģ†ŒģŠ¤ėÆøģŠ¤ķ“ė¼ģø ė°”ģ“ģ˜¤ė”œģ§€ģ¹¼ģ¦ˆ ģ—ģŠ¤.ģ—ģ“. ź±“ģ”° ź³µģ •
CN100351260C (zh) 2002-11-12 2007-11-28 åøƒčµ–ę±‰å§†å¦‡å„³åŒ»é™¢ 葔萄ēƒčŒę„ŸęŸ“ēš„多ē³–ē–«č‹—
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5ā€™ cpg nucleic acids and methods of use
JP2006520746A (ja) 2002-12-27 2006-09-14 ć‚«ć‚¤ćƒ­ćƒ³ ć‚³ćƒ¼ćƒćƒ¬ć‚¤ć‚·ćƒ§ćƒ³ ćƒŖćƒ³č„‚č³Ŗć‚’å«ć‚€å…ē–«åŽŸę€§ēµ„ęˆē‰©
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
WO2004067030A2 (en) * 2003-01-30 2004-08-12 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
CN102366630B (zh) 2003-03-07 2015-04-01 ęƒ ę°ęŽ§č‚”å…¬åø ē”ØäŗŽęŠ—åŒ»é™¢å†…ę„ŸęŸ“ēš„免ē–«ēš„多ē³–-葔萄ēƒčŒč”Ø面ē²˜é™„ē“ č½½ä½“蛋ē™½ē¼€åˆē‰©
EP1601689B1 (en) * 2003-03-13 2007-11-28 GlaxoSmithKline Biologicals S.A. Purification process for bacterial cytolysin
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
CA2528007C (en) 2003-06-02 2012-03-27 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
BRPI0415025A (pt) 2003-10-02 2006-12-12 Chiron Srl vacinas lƬquidas para sorogrupos meningocĆ³cicos mĆŗltiplos
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
PT1740217E (pt) 2004-04-30 2011-08-02 Novartis Ag VacinaĆ§Ć£o meningocĆ³cica conjugada
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
US7444197B2 (en) * 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
EP1765313A2 (en) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US9034345B2 (en) 2005-01-27 2015-05-19 Children's Hospital & Research Center Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
EP1858919B1 (en) 2005-02-18 2012-04-04 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
WO2006089264A2 (en) 2005-02-18 2006-08-24 Novartis Vaccines And Diagnostics Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
AU2006235013B2 (en) 2005-04-08 2011-11-03 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP1871411A4 (en) 2005-04-18 2010-07-21 Novartis Vaccines & Diagnostic EXPRESSION OF HEPATITIS B VIRUS SURFACE ANTIGEN FOR VACCINE MANUFACTURE
PE20070163A1 (es) 2005-06-27 2007-03-01 Glaxosmithkline Biolog Sa Composicion inmunogenica de conjugados de sacaridos de n. meningitidis
CN102973929B (zh) 2005-09-01 2017-04-26 čÆŗ华ē–«č‹—å’ŒčÆŠę–­ęœ‰é™äø¤åˆå…¬åø å«č”€ęø…ē¾¤c脑膜ē‚ŽēƒčŒēš„多价ē–«č‹—
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa ꖰē©Žēµ„合ē‰©
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP3020411A1 (en) * 2005-12-22 2016-05-18 GlaxoSmithKline Biologicals s.a. Vaccine
CN101374859B (zh) * 2006-01-17 2014-11-26 é˜æꁩĀ·ē¦ę–Æę ¼ä¼¦ ꖰēš„č”Øé¢å¤–éœ²ęµę„Ÿå—œč”€čŒč›‹ē™½č“Ø(蛋ē™½č“ØEļ¼›pE)
CN101024079B (zh) * 2006-02-17 2012-02-01 ē¦å·žę˜Œę™–ē”Ÿē‰©å·„ēØ‹ęœ‰é™å…¬åø č‚ŗē‚Žé“¾ēƒčŒå¤šē³–-å¤–č†œč›‹ē™½ē»“合ē–«č‹—åŠåˆ¶å¤‡ę–¹ę³•
KR20150038626A (ko) * 2006-03-17 2015-04-08 ė” ź±°ė²„ėؼķŠø ģ˜¤ėøŒ ė” ģœ ė‚˜ģ“ķ‹°ė“œ ģŠ¤ķ…Œģ“ģø  ģ˜¤ėøŒ ģ•„ė©”ė¦¬ģ¹“ ģ—ģ¦ˆ ė ˆķ”„ė¦¬ģ  ķ‹°ė“œ ė°”ģ“ ė” ģ„øķ¬ėŸ¬ķ…Œė¦¬ ģ˜¤ėøŒ ė” ė””ķŒŒķŠøėؼķŠø ģ˜¤ėøŒ ķ—¬ģŠ¤ ģ•¤ė“œ ķœ“ėؼ ģ„œė¹„ģ‹œģ¦ˆ ė³µķ•© ė‹¤ź°€ ė©“ģ—­ģ›ģ„± ģ½˜ģ„¬ź²Œģ“ķŠøģ˜ ģ œģ”° ė°©ė²•
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
PL2004225T3 (pl) 2006-03-22 2012-09-28 Novartis Ag Schematy immunizacji koniugatami meningokokowymi
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
EP2010537B1 (en) 2006-03-23 2011-12-28 Novartis AG Imidazoquinoxaline compounds as immunomodulators
EA015833B1 (ru) * 2006-03-30 2011-12-30 Š“Š»Š°ŠŗсŠ¾ŃŠ¼ŠøтŠŗŠ»Š°Š¹Š½ Š‘Š°Š¹Š¾Š»Š¾Š“Š¶ŠøŠŗŠ°Š»Ń Š”.Š. Š˜Š¼Š¼ŃƒŠ½Š¾Š³ŠµŠ½Š½Š°Ń ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøя
PE20080774A1 (es) * 2006-03-30 2008-08-08 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende pnag de estafilococos conjugada con una proteina portadora y polisacarido u oligosacarido capsular de s. aureus
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
US20100015168A1 (en) * 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
CL2007002909A1 (es) * 2006-10-10 2008-04-18 Wyeth Corp Metodo para reduccion o extraccion de impurezas de proteinas a partir de lisado celular de streptoccocus pneumoniae que comprende calentar dicho lisado, separar a los precipitantes a partir de dicho lisado produciendo un lisado que contiene polisacar
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
MX2009013949A (es) * 2007-06-26 2010-05-24 Glaxosmithkline Biolog Sa Vacuna que comprende conjugados de polisacƔrido capsular de streptococcus pneumoniae.
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
AU2008299376B2 (en) 2007-09-12 2013-02-28 Glaxosmithkline Biologicals S.A. GAS57 mutant antigens and GAS57 antibodies
ES2383231T3 (es) 2007-10-19 2012-06-19 Novartis Ag Formulaciones para vacunas meningocĆ³cicas
WO2009062132A2 (en) 2007-11-09 2009-05-14 California Institute Of Technology Immunomodulating compounds and related compositions and methods
US8815253B2 (en) 2007-12-07 2014-08-26 Novartis Ag Compositions for inducing immune responses
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2009081274A2 (en) 2007-12-21 2009-07-02 Novartis Ag Mutant forms of streptolysin o
US8226959B2 (en) * 2008-02-01 2012-07-24 Newcastle Innovation Pty Ltd Vaccine compositions
EP2886551A3 (en) 2008-02-21 2015-09-23 Novartis AG Meningococcal fhbp polypeptides
EP2631245A1 (en) 2008-03-10 2013-08-28 Children's Hospital & Research Center at Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
KR20110031393A (ko) 2008-07-21 2011-03-25 ė” ėøŒė¦¬ź²€ ģ•¤ė“œ ģš°ėؼģ¦ˆ ķ•˜ģŠ¤ķ”¼ķ„ø, ģøķ¬. ķ•©ģ„± ė² ķƒ€-1,6 źø€ė£Øģ½”ģ‚¬ėƼ ģ˜¬ė¦¬ź³ ė‹¹ģ— ź“€ķ•œ ė°©ė²• ė° ģ”°ģ„±ė¬¼
DK2349520T3 (en) 2008-10-27 2016-08-15 Glaxosmithkline Biologicals Sa Purification Procedure for Group A Streptococcus Carbohydrate
SG186611A1 (en) 2008-12-09 2013-01-30 Pfizer Vaccines Llc Ige ch3 peptide vaccine
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
JP2012512240A (ja) 2008-12-17 2012-05-31 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ ćƒ˜ćƒ¢ć‚°ćƒ­ćƒ“ćƒ³å—å®¹ä½“ć‚’å«ć‚€é«„č†œē‚ŽčŒćƒÆć‚Æćƒćƒ³
CA2748788C (en) 2009-01-05 2021-02-09 Epitogenesis Inc. The use of a composition comprising mustard oil, catechin, and vitamin a for modulating an immune response
AU2010204139A1 (en) 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
CN102438649A (zh) 2009-03-24 2012-05-02 čÆŗåŽęœ‰é™å…¬åø 脑膜ē‚ŽēƒčŒh因子ē»“åˆč›‹ē™½å’Œč‚ŗē‚ŽēƒčŒē»“合ē³–ēš„ē»„合ē‰©
BRPI1009828A2 (pt) 2009-03-24 2019-03-12 Novartis Ag adjuvante de proteĆ­na de ligaĆ§Ć£o de fator h meningocĆ³cica
CA2758490C (en) 2009-04-14 2023-05-02 Novartis Ag Compositions for immunising against staphylococcus aureus
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
CN107096020A (zh) 2009-06-22 2017-08-29 ęƒ ę°ęœ‰é™č“£ä»»å…¬åø é‡‘é»„č‰²č‘”č„ēƒčŒęŠ—原ēš„免ē–«åŽŸę€§ē»„合ē‰©
BRPI1011753B8 (pt) 2009-06-22 2021-05-25 Wyeth Llc conjugados imunogĆŖnicos de polissacarĆ­deo capsular de staphylococcus aureus de sorotipos 5 e 8, seu uso e composiƧƵes que os compreendem
US8647621B2 (en) 2009-07-27 2014-02-11 Fina Biosolutions, Llc Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
RU2518291C2 (ru) 2009-07-30 2014-06-10 ŠŸŃ„Š°Š¹Š·ŠµŃ€ Š’эŠŗсŠøŠ½Ń Š­Š»Š­Š»Š”Šø ŠŠ½Ń‚ŠøŠ³ŠµŠ½Š½Ń‹Šµ tau-ŠæŠµŠæтŠøŠ“ы Šø Šøх ŠæрŠøŠ¼ŠµŠ½ŠµŠ½Šøя
EP3017828A1 (en) 2009-08-27 2016-05-11 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
AU2010290931B2 (en) 2009-09-03 2014-02-06 Pfizer Vaccines Llc PCSK9 vaccine
EP2475385A1 (en) 2009-09-10 2012-07-18 Novartis AG Combination vaccines against respiratory tract diseases
CN102917730A (zh) 2009-10-27 2013-02-06 čÆŗåŽęœ‰é™å…¬åø äæ®é„°ēš„č„‘č†œē‚ŽēƒčŒfHBPå¤šč‚½
EP3199177A1 (en) 2009-10-30 2017-08-02 GlaxoSmithKline Biologicals S.A. Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
SG10201506165TA (en) * 2009-12-17 2015-09-29 Fina Biosolutions Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
EP3257525A3 (en) 2009-12-22 2018-02-28 Celldex Therapeutics, Inc. Vaccine compositions
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
CN105315351A (zh) 2010-03-30 2016-02-10 å„„å…‹å…°å„æē«„医院及ē ”ē©¶äø­åæƒ ę”¹ę€§ēš„h因子ē»“åˆč›‹ē™½ļ¼ˆfhbpļ¼‰åŠå…¶ä½æē”Øę–¹ę³•
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
EP2555753B1 (en) 2010-04-07 2018-08-01 California Institute of Technology Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
US20110287048A1 (en) * 2010-05-20 2011-11-24 Round June L Antigen Specific Tregs and related compositions, methods and systems
CN102933267B (zh) 2010-05-28 2015-05-27 ę³°ē‰¹é‡Œę–ÆåœØēŗæ公åø äŗ¤äŗ’å¼ę··åˆå¼‚ę­„č®”ē®—ęœŗęøøꈏåŸŗē”€ē»“ęž„
SI2575870T1 (sl) * 2010-06-04 2017-01-31 Wyeth Llc Formulacije cepiva
EP2576613A1 (en) 2010-06-07 2013-04-10 Pfizer Inc. Her-2 peptides and vaccines
EP2942061A3 (en) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
EP2667852B1 (en) 2011-01-27 2016-11-09 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with crystallisation inhibitors
TR201811280T4 (tr) 2011-03-02 2018-08-27 Glaxosmithkline Biologicals Sa DĆ¼ÅŸĆ¼k antijen ve/ veya adjuvan dozları olan karma aşılar.
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
US10357568B2 (en) 2011-03-24 2019-07-23 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with phospholipids
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
UA111845C2 (uk) 2011-05-06 2016-06-24 ŠŸŃŒŠ¾Ń‚Ń€ Š“Ń”Š½Š½Š°Š“ьєŠ²Ń–ч ŠŠæŠ°Ń€Ń–Š½ Š•ŠŗŠ·Š¾ŠæŠ¾Š»Ń–сŠ°Ń…Š°Ń€ŠøŠ“ Š±Š°ŠŗтŠµŃ€Ń–Ń— shigella sonnei, сŠæŠ¾ŃŃ–Š± Š¹Š¾Š³Š¾ Š¾Š“ŠµŃ€Š¶Š°Š½Š½Ń тŠ° Š²Š°ŠŗцŠøŠ½Š° і фŠ°Ń€Š¼Š°Ń†ŠµŠ²Ń‚ŠøчŠ½Š° ŠŗŠ¾Š¼ŠæŠ¾Š·Šøція, щŠ¾ Š¹Š¾Š³Š¾ Š¼Ń–ŃŃ‚ŃŃ‚ŃŒ
CN103717235A (zh) 2011-06-24 2014-04-09 埃ēš®ę‰˜å‰å°¼č„æę–Æęœ‰é™å…¬åø 作äøŗęŠ—åŽŸē‰¹å¼‚ę€§å…ē–«č°ƒčŠ‚剂ēš„åŒ…å«é€‰ę‹©ēš„č½½ä½“ć€ē»“ē”Ÿē“ ć€å•å®å’Œē±»é»„é…®ēš„ē»„合ēš„čÆē‰©ē»„合ē‰©
CN103764171B (zh) 2011-07-08 2016-08-17 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø é…Ŗę°Øé…øčæžęŽ„ę–¹ę³•
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
CN103917245B (zh) 2011-09-14 2017-06-06 č‘›å…°ē“ å²åƆäøå…‹čŽ±ę©ē”Ÿē‰©ęœ‰é™å…¬åø ē”ØäŗŽåˆ¶å¤‡ē³–ā€‘蛋ē™½č“Øē³–ē¼€åˆē‰©ēš„ę–¹ę³•
WO2013043518A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
AU2012335208B2 (en) 2011-11-07 2017-08-31 Glaxosmithkline Biologicals S.A. Carrier molecule comprising a spr0096 and a spr2021 antigen
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
JP6084631B2 (ja) 2011-12-08 2017-02-22 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ ļ¼£ļ½Œļ½ļ½“ļ½”ļ½’ļ½‰ļ½„ļ½‰ļ½•ļ½ļ½„ļ½‰ļ½†ļ½†ļ½‰ļ½ƒļ½‰ļ½Œļ½…ęƒē“ ćƒ™ćƒ¼ć‚¹ć®ćƒÆć‚Æćƒćƒ³
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
EP2797624A1 (en) 2011-12-29 2014-11-05 Novartis AG Adjuvanted combinations of meningococcal factor h binding proteins
EP2817320A1 (en) 2012-02-24 2014-12-31 Novartis AG Pilus proteins and compositions
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
SA115360586B1 (ar) 2012-03-09 2017-04-12 ŁŲ§ŁŠŲ²Ų± Ų§Ł†Łƒ ŲŖŲ±ŁƒŁŠŲØŲ§ŲŖ Ł„Ų¹Ł„Ų§Ų¬ Ų§Ł„Ų§Ł„ŲŖŁ‡Ų§ŲØ Ų§Ł„Ų³Ų­Ų§Ų¦ŁŠ Ų§Ł„ŲØŁƒŲŖŁŠŲ±ŁŠ ŁˆŲ·Ų±Ł‚ Ł„ŲŖŲ­Ų¶ŁŠŲ±Ł‡Ų§
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
BR112014026812A8 (pt) 2012-04-26 2022-10-04 Novartis Ag Antƭgenos e combinaƧƵes de antƭgenos
SG10201603896RA (en) 2012-05-04 2016-07-28 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
KR20150021933A (ko) 2012-05-22 2015-03-03 ė…øķŒŒė„“ķ‹°ģŠ¤ ģ•„ź²Œ ģˆ˜ė§‰ģ—¼źµ¬ź·  ķ˜ˆģ²­źµ° x ķ¬ķ•©ģ²“
KR102057217B1 (ko) * 2012-06-20 2020-01-22 ģ—ģŠ¤ģ¼€ģ“ė°”ģ“ģ˜¤ģ‚¬ģ“ģ–øģŠ¤ ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
CN104602705A (zh) 2012-09-06 2015-05-06 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø 蔀ęø…ē»„b脑膜ē‚ŽēƒčŒå’Œd/t/pēš„č”åˆē–«č‹—
KR20150073160A (ko) 2012-10-03 2015-06-30 źø€ė½ģ†ŒģŠ¤ėÆøģŠ¤ķ“ė¼ģø ė°”ģ“ģ˜¤ė”œģ§€ģ¹¼ģ¦ˆ ģ—ģŠ¤.ģ—ģ“. ė©“ģ—­ģ›ģ„± ģ”°ģ„±ė¬¼
KR20150065878A (ko) 2012-10-12 2015-06-15 źø€ė½ģ†ŒģŠ¤ėÆøģŠ¤ķ“ė¼ģø ė°”ģ“ģ˜¤ė”œģ§€ģ¹¼ģ¦ˆ ģ—ģŠ¤.ģ—ģ“. ģ”°ķ•© ė°±ģ‹ ģ—ģ„œ ģ‚¬ģš©ķ•˜źø° ģœ„ķ•œ ź°€źµė˜ģ§€ ģ•Šģ€ ė¬“ģ„øķ¬ ė°±ģ¼ķ•“ ķ•­ģ›
KR20150072444A (ko) * 2012-10-17 2015-06-29 źø€ė½ģ†ŒģŠ¤ėÆøģŠ¤ķ“ė¼ģø ė°”ģ“ģ˜¤ė”œģ§€ģ¹¼ģ¦ˆ ģ—ģŠ¤.ģ—ģ“. ķ•˜ė‚˜ ģ“ģƒģ˜ ģŠ¤ķŠøė ™ķ† ģ½”ģ»¤ģŠ¤ ė‰“ėŖØė‹ˆģ•  ģŗ”ģŠ ģ‚¬ģ¹“ė¼ģ“ė“œ ģ»Øģ„¬ź²Œģ“ķŠø ė° ķ•“ėŖØķ•„ė£ØģŠ¤ ģøķ”Œė£Øģ—”ģžė”œė¶€ķ„°ģ˜ ė‹Øė°±ģ§ˆ ļ¼„ ė°ļ¼ė˜ėŠ” ļ¼°ļ½‰ļ½Œļ¼”ė„¼ ķ¬ķ•Øķ•˜ėŠ” ė‹Øė°±ģ§ˆ ģ„±ė¶„ģ„ ķ¬ķ•Øķ•˜ėŠ” ė©“ģ—­ģ›ģ„± ģ”°ģ„±ė¬¼
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
KR20140075201A (ko) * 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
KR20140075196A (ko) 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
US9827190B2 (en) 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
EP2994161B1 (en) 2013-05-10 2020-10-28 California Institute of Technology Probiotic prevention and treatment of colon cancer
WO2015132619A1 (en) 2013-05-15 2015-09-11 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use
CN103386126B (zh) * 2013-06-25 2015-06-17 北äŗ¬ē§‘å…“ē”Ÿē‰©åˆ¶å“ęœ‰é™å…¬åø äø€ē§å«č‚ é“ē—…ęÆ’ęŠ—åŽŸēš„多价免ē–«åŽŸę€§ē»„合ē‰©
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
ES2883343T3 (es) 2014-01-21 2021-12-07 Pfizer PolisacƔridos capsulares de Streptococcus pneumoniae y conjugados de los mismos
SG11201604728XA (en) 2014-01-21 2016-08-30 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
SMT202000704T1 (it) 2014-02-28 2021-01-05 Glaxosmithkline Biologicals Sa POLIPEPTIDI DI fHbp DI MENINGOCOCCO MODIFICATI
EP2921856B1 (en) * 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
CN104829711B (zh) * 2014-04-08 2018-04-03 北äŗ¬å¤©ęˆę–°č„‰ē”Ÿē‰©ęŠ€ęœÆęœ‰é™å…¬åø 脑膜ē‚ŽēƒčŒčšč†œå¤šē³–å•å…‹éš†ęŠ—ä½“åŠå…¶åŗ”ē”Ø
KR102761870B1 (ko) 2014-07-23 2025-02-05 ģ¹ ė“œėŸ°ģ¦ˆ ķ•˜ģŠ¤ķ”¼ķ‹€ ģ•¤ė“œ ė¦¬ģØģ¹˜ ģ„¼ķ„° ģ•³ ģ˜¤ķ“ėžœė“œ ģøģž h ź²°ķ•© ė‹Øė°±ģ§ˆ ė³€ģ“ģ²“ ė° ģ“ģ˜ ģ‚¬ģš© ė°©ė²•
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
MX395525B (es) 2015-01-15 2025-03-25 Pfizer Composiciones inmunogenicas para usar en vacunas neumococicas.
CN104548090B (zh) * 2015-01-27 2016-11-30 äø­å›½ē§‘学院čæ‡ēØ‹å·„ē؋ē ”ē©¶ę‰€ äø€ē§Ī²-葔聚ē³–äæ®é„°ēš„č„‘č†œē‚Žå¤šē³–ē»“合ē–«č‹—åŠå…¶åˆ¶å¤‡ę–¹ę³•
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
CA2991544A1 (en) 2015-07-07 2017-01-12 Affiris Ag Vaccines for the treatment and prevention of ige mediated diseases
BR112018000087A2 (pt) 2015-07-21 2018-09-04 Pfizer Inc. composiƧƵes imunogĆŖnicas que compreendem antĆ­genos de sacarĆ­deos capsulares conjugados, kits que compreendem as mesmas e usos das mesmas
EP4480544A3 (en) 2015-08-25 2025-03-26 Babita Agrawal Immunomodulatory compositions andmethods of use thereof
CN117229414A (zh) 2015-10-08 2023-12-15 č‰¾ä¼Æ唔大学ē†äŗ‹ä¼š äø™åž‹č‚ē‚Žē—…ęƒe1/e2异äŗŒčšä½“及其ē”Ÿäŗ§ę–¹ę³•
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
SG11201804597TA (en) 2015-12-04 2018-06-28 Dana Farber Cancer Inst Inc Vaccination with mica/b alpha 3 domain for the treatment of cancer
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
SG11201805621SA (en) 2016-01-19 2018-08-30 Pfizer Cancer vaccines
BE1024634B1 (fr) 2016-04-05 2018-05-14 Gsk Vaccines S.R.L. Compositions immunogenes
WO2017220753A1 (en) 2016-06-22 2017-12-28 MAX-PLANCK-Gesellschaft zur Fƶrderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
CN109862908B (zh) 2016-08-05 2023-05-02 圣čÆŗč²Ā·åø•ę–Æ图尔公åø 多价č‚ŗē‚ŽēƒčŒå¤šē³–-蛋ē™½č“Øē¼€åˆē‰©ē»„合ē‰©
EP3493840B1 (en) 2016-08-05 2022-08-24 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
JP7104027B2 (ja) 2016-09-02 2022-07-20 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  ę·‹čŒć«åÆ¾ć™ć‚‹ćƒÆć‚Æćƒćƒ³
EP3522916A2 (en) 2016-10-07 2019-08-14 Enterome S.A. Immunogenic compounds for cancer therapy
US11478537B2 (en) 2016-10-07 2022-10-25 Enterome S.A. Immunogenic compounds for cancer therapy
US20210108002A1 (en) 2016-12-06 2021-04-15 Glaxosmithkline Biologicals Sa Purification Process For Capsular Polysaccharide
BR112019014833A2 (pt) 2017-01-20 2020-04-14 Pfizer composiƧƵes imunogĆŖnicas para uso em vacinas pneumococais
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR102101879B1 (ko) * 2017-03-15 2020-05-29 ģ£¼ģ‹ķšŒģ‚¬ ģ—˜ģ§€ķ™”ķ•™ ė‹¤ź°€ ķė “źµ¬ź·  ė°±ģ‹  ģ”°ģ„±ė¬¼
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2018178264A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
KR20240018697A (ko) 2017-06-10 2024-02-13 ģøė²¤ķŠøķ”„ė¼ģ“ģ¦ˆ ģøķ¬. ė©“ģ—­ģ›ģ„±ź³¼ ķ•­ģ›ķ•­ģ²“ ź²°ķ•©ģ„±ģ“ ź°œģ„ ėœ 2ź°€ ė˜ėŠ” ė‹¤ź°€ ģ ‘ķ•©ģ²“ ė‹¤ė‹¹ė„˜ė„¼ ź°€ģ§„ ė‹¤ź°€ ģ ‘ķ•©ģ²“ ė°±ģ‹ 
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
BR112020001768A2 (pt) 2017-08-14 2020-09-29 Glaxosmithkline Biologicals S.A. mĆ©todo de reforƧar uma resposta imune prĆ©-existente contra haemophilus influenzae e moraxella catarrhalis nĆ£o tipĆ”veis em um indivĆ­duo, e, protocolo de vacinaĆ§Ć£o.
EP3691677A4 (en) 2017-10-04 2021-07-07 Pogona, Llc COMPOSITIONS OF SACCHARIDE-POLYPEPTIDE CONJUGATES AND THEIR METHODS OF USE
CN117982633A (zh) 2017-12-06 2024-05-07 é»˜ę²™äøœęœ‰é™č“£ä»»å…¬åø 包含č‚ŗē‚Žé“¾ēƒčŒå¤šē³–蛋ē™½ē¼€åˆē‰©ēš„ē»„合ē‰©åŠå…¶ä½æē”Øę–¹ę³•
IL276229B2 (en) 2018-02-05 2024-01-01 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
CA3089007A1 (en) 2018-02-05 2019-08-08 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
CA3094262A1 (en) 2018-04-11 2019-10-17 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
US20210106652A1 (en) 2018-04-11 2021-04-15 Enterome S.A. Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation
EP3782642A4 (en) 2018-04-18 2022-04-13 SK Bioscience Co., Ltd. CAPSULE POLYSACCHARIDES FROM STREPTOCOCCUS PNEUMONIAE AND CONJUGATES THEREOF
BR112021000529A2 (pt) 2018-07-19 2021-04-06 Glaxosmithkline Biologicals S.A. Processos para preparar polissacarĆ­deos secos
CA3107077A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
WO2020120569A2 (en) 2018-12-12 2020-06-18 Glaxosmithkline Biologicals Sa Modified carrier proteins for o-linked glycosylation
CR20210333A (es) 2018-12-19 2021-08-18 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacƔrido de streptococcus pneumoniae con proteƭna y sus mƩtodos de uso
CA3126492A1 (en) 2019-01-11 2020-07-16 Northwestern University Bioconjugate vaccines synthesis in prokaryotic cell lysates
WO2020163512A1 (en) 2019-02-05 2020-08-13 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
EP3923982A1 (en) 2019-02-11 2021-12-22 Pfizer Inc. Neisseria meningitidiscompositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ē“°čŒå¤šē³–锞悒ē²¾č£½ć™ć‚‹ćŸć‚ć®ę–¹ę³•
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3956666A1 (en) 2019-04-18 2022-02-23 GlaxoSmithKline Biologicals S.A. Antigen binding proteins and assays
CA3139257A1 (en) 2019-05-10 2020-11-19 Glaxosmithkline Biologicals Sa Conjugate production
EP4010014A1 (en) 2019-08-05 2022-06-15 GlaxoSmithKline Biologicals S.A. Immunogenic composition
MX2022001489A (es) 2019-08-05 2022-03-02 Glaxosmithkline Biologicals Sa Proceso para la preparacion de una composicion que comprende un polipeptido de proteina d.
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
MX2022004598A (es) 2019-10-16 2022-09-23 Enterome S A Compuestos inmunogenicos para el tratamiento del cancer suprarrenal.
CN114667343A (zh) 2019-11-01 2022-06-24 č¾‰ē‘žå¤§čÆ厂 å¤§č‚ ę†čŒē»„合ē‰©åŠå…¶ę–¹ę³•
SI4021487T1 (sl) 2019-11-15 2024-03-29 Enterome S.A., Antigenski peptidi za preprečevanje in zdravljenje b-celične malignosti
JP2023503086A (ja) 2019-11-22 2023-01-26 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  ē“°čŒć‚µćƒƒć‚«ćƒŖćƒ‰č¤‡åˆē³–č³ŖćƒÆć‚Æćƒćƒ³ć®ē”Øę³•åŠć³ē”Ø量
WO2021138495A1 (en) * 2019-12-30 2021-07-08 Fraunhofer Usa, Inc. Particles for multi-dose delivery
WO2021165847A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
CN115605498A (zh) 2020-02-23 2023-01-13 č¾‰ē‘žå…¬åøļ¼ˆUsļ¼‰ å¤§č‚ ę†čŒē»„合ē‰©åŠå…¶ę–¹ę³•
CN111588847B (zh) * 2020-05-18 2023-05-26 å¹æ州äø­åŒ»čÆ大学(å¹æ州äø­åŒ»čÆē ”ē©¶é™¢) äø€ē§å«ęœ‰å•ē£·é…ø化ēš„č„‚č“ØaäøŽē³–ęŠ—åŽŸēš„ē¼€åˆē‰©åŠå…¶åˆ¶å¤‡ę–¹ę³•å’Œåŗ”ē”Ø
US20230250142A1 (en) 2020-06-12 2023-08-10 Glaxosmithkline Biologicals Sa Dock tag system
EP4192499A4 (en) 2020-08-10 2024-09-25 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
MX2023004912A (es) 2020-10-27 2023-05-16 Pfizer Composiciones de escherichia coli y metodos de las mismas.
MX2023005221A (es) 2020-11-04 2023-05-16 Pfizer Composiciones inmunogenicas para uso en vacunas neumococicas.
WO2022101745A2 (en) 2020-11-10 2022-05-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
MX2023009728A (es) 2021-02-19 2023-08-30 Sanofi Pasteur Inc Vacuna recombinante meningococica b.
US20240148849A1 (en) 2021-02-22 2024-05-09 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
EP4346892A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2022249107A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2022391752A1 (en) 2021-11-18 2024-06-13 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
KR20240128715A (ko) 2022-01-13 2024-08-26 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ģ ‘ķ•©ėœ ķ”¼ė§‰ ģ‚¬ģ¹“ė¼ģ“ė“œ ķ•­ģ›ģ„ ķ¬ķ•Øķ•˜ėŠ” ė©“ģ—­ģ›ģ„± ģ”°ģ„±ė¬¼ ė° ź·øģ˜ ģš©ė„
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
US20250205324A1 (en) 2022-03-31 2025-06-26 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
CN119317445A (zh) 2022-05-11 2025-01-14 č¾‰ē‘žå…¬åø ē”ØäŗŽē”Ÿäŗ§å«ęœ‰é˜²č…å‰‚ēš„ē–«č‹—制剂ēš„ę–¹ę³•
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
CN120265317A (zh) 2022-11-22 2025-07-04 č¾‰ē‘žå…¬åø 包含ē»ē¼€åˆēš„čšč†œē³–ęŠ—åŽŸēš„免ē–«åŽŸę€§ē»„合ē‰©åŠå…¶ē”Ø途
IL321069A (en) 2022-12-01 2025-07-01 Pfizer Pneumococcal conjugate vaccine preparations
EP4661911A1 (en) 2023-02-10 2025-12-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2024246082A1 (en) 2023-03-30 2025-10-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2024255922A1 (en) 2023-04-14 2025-10-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025109417A1 (en) 2023-11-21 2025-05-30 Panacea Biotec Limited Immunogenic composition of haemophilus influenzae conjugated to protein d
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
CN120404993B (zh) * 2025-07-03 2025-10-03 ęˆéƒ½čæˆē§‘åŗ·ē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø äø€ē§ę£€ęµ‹ę ·ęœ¬äø­mplēš„ę–¹ę³•åŠå…¶ē›ø关åŗ”ē”Ø

Family Cites Families (58)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE205534T1 (de) * 1988-12-16 2001-09-15 Nederlanden Staat Pneumolysin-mutanten und pneumokokken-impfstoffe daraus
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
UA40597C2 (uk) 1992-06-25 2001-08-15 Š”Š¼Ń–Ń‚ŠŗŠ»Š°Š¹Š½ Š‘ічŠµŠ¼ Š‘Š°Š¹Š¾Š»Š¾Š“Š¶Ń–ŠŗŠ°Š»Ń Š”.Š. Š’Š°ŠŗцŠøŠ½Š½Š° ŠŗŠ¾Š¼ŠæŠ¾Š·Šøція,сŠæŠ¾ŃŃ–Š± Š»Ń–ŠŗуŠ²Š°Š½Š½Ń ссŠ°Š²Ń†Ń–Š², щŠ¾ стрŠ°Š¶Š“Š°ŃŽŃ‚ŃŒ Š°Š±Š¾ сŠæрŠøŠ¹Š½ŃŃ‚Š»ŠøŠ²Ń– Š“Š¾ іŠ½Ń„ŠµŠŗції, сŠæŠ¾ŃŃ–Š± Š»Ń–ŠŗуŠ²Š°Š½Š½Ń ссŠ°Š²Ń†Ń–Š², щŠ¾ стрŠ°Š¶Š“Š°ŃŽŃ‚ŃŒ Š½Š° рŠ°Šŗ, сŠæŠ¾ŃŃ–Š± Š¾Š“ŠµŃ€Š¶Š°Š½Š½Ń Š²Š°ŠŗцŠøŠ½Š½Š¾Ń— ŠŗŠ¾Š¼ŠæŠ¾Š·Šøції, ŠŗŠ¾Š¼ŠæŠ¾Š·Šøція Š°Š“'юŠ²Š°Š½Ń‚Ń–Š²
DK0618813T3 (da) * 1992-09-16 2002-03-11 Univ Tennessee Res Corp Antigen for M-hybridprotein og bƦrer for gruppe A streptococcal vaccine
CN1087176C (zh) 1993-03-23 2002-07-10 史åƆę–Æå…‹čŽ±Ā·ęÆ”å„‡ę›¼ē”Ÿē‰©å…¬åø å«ęœ‰3ļ¼o脱酰åŸŗ单ē£·é…°č„‚aēš„ē–«č‹—制剂
ES2185658T3 (es) 1993-05-18 2003-05-01 Univ Ohio State Res Found Vacuna para la otitis media.
KR100376361B1 (ko) 1993-09-22 2003-07-18 ķ—Øė¦¬ ģ— . ģž­ģŠØ ķŒŒģš“ė°ģ“ģ…˜ ķ¬ ė” ģ–“ė“œė²¤ģŠ¤ėؼķŠø ģ˜¤ėøŒ ė°€ė¦¬ķ„°ė¦¬ ė©”ė””ģ‹  ė©“ģ—­ģ›ģ„±źµ¬ģ”°ģ²“ģ˜ģ œģ”°ė„¼ģœ„ķ•˜ģ—¬ģ‹ ź·œķ•œģ‹œģ•„ė‹ė ˆģ“ķŒ…ģ‹œģ•½ģ„ģ‚¬ģš©ķ•˜ģ—¬ģš©ķ•“ģ„±ķƒ„ģˆ˜ķ™”ė¬¼ģ„ķ™œģ„±ķ™”ķ•˜ėŠ”ė°©ė²•
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
KR19990007858A (ko) * 1995-04-17 1999-01-25 ģ”“ ė”ėø”ģœ .ė”œģš° ė°•ķ…Œė¦¬ģ•„ģ˜ ė¦¬ķ¬ķ”„ė”œķ…Œģøģœ¼ė”œ ķ“ė¦¬ģ‚¬ģ¹“ė¼ģ“ė“œģ— ėŒ€ķ•œ ė©“ģ—­ė°˜ģ‘ģ˜ ģœ ė„ė° ź°•ķ™”
UA56132C2 (uk) * 1995-04-25 2003-05-15 Š”Š¼Ń–Ń‚ŠŗŠ»Š°Š¹Š½ Š‘ічŠµŠ¼ Š‘Š°Š¹Š¾Š»Š¾Š“Š¶Ń–ŠŗŠ°Š»Ń Š”.Š. ŠšŠ¾Š¼ŠæŠ¾Š·Šøція Š²Š°ŠŗцŠøŠ½Šø (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± стŠ°Š±Ń–Š»Ń–Š·Š°Ń†Ń–Ń— qs21 Š²Ń–Š“Š½Š¾ŃŠ½Š¾ Š³Ń–Š“рŠ¾Š»Ń–Š·Ńƒ (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± ŠæрŠøŠ³Š¾Ń‚ŃƒŠ²Š°Š½Š½Ń ŠŗŠ¾Š¼ŠæŠ¾Š·Šøції Š²Š°ŠŗцŠøŠ½Šø
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
AU700080B2 (en) 1995-06-07 1998-12-17 Biochem Vaccines Inc. Streptococcal heat shock proteins members of the HSP70 family
HUP9802199A3 (en) 1995-06-07 1999-07-28 Smithkline Beecham Biolog Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein and use of
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
ES2262177T3 (es) 1996-05-01 2006-11-16 The Rockefeller University Proteinas de union a colina para vacunas frente a neumococos.
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
JPH102001A (ja) * 1996-06-15 1998-01-06 Okajima Kogyo Kk ć‚°ćƒ¬ćƒ¼ćƒćƒ³ć‚°
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
JP2001502925A (ja) 1997-06-03 2001-03-06 ć‚³ćƒŽćƒ¼ćƒˆ ćƒ©ćƒœćƒ©ćƒˆćƒŖćƒ¼ć‚ŗ ćƒŖ惟惆惃惉 ćƒ¢ćƒ©ć‚Æć‚»ćƒ©ć®ćƒ©ć‚Æ惈惕悧ćƒŖćƒ³å—å®¹ä½“éŗ伝子
WO1999003884A2 (en) 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
US6709658B1 (en) * 1998-02-12 2004-03-23 Wyeth Holdings Corporation Pneumococcal vaccines formulated with interleukin-12
CA2325340A1 (en) 1998-04-07 1999-10-14 Medimmune, Inc. Derivatives of pneumococcal choline binding proteins for vaccines
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
KR100704826B1 (ko) 1998-08-19 2007-04-09 ė°•ģŠ¤ķ„° ķ—¬ģ“°ģ¼€ģ–“ ģ—ģŠ¤.ģ—ģ“. ļ¼®-ģ•„ķ¬ė¦“ė”œģ¼ķ™”ėœ ķ“ė¦¬ģ‚¬ģ¹“ė¼ģ“ė“œė„¼ ģ‚¬ģš©ķ•˜ģ—¬ ģ œģ”°ėœė°±ģ‹ ģœ¼ė”œģ„œ ģ‚¬ģš©ķ•˜źø°ģ— ģ ķ•©ķ•œ ė©“ģ—­ģ›ģ„±Ī²-ķ”„ė”œķ”¼ģ˜Øģ•„ėÆøė„-ź²°ķ•© ķ“ė¦¬ģ‚¬ģ¹“ė¼ģ“ė“œ ė‹Øė°±ģ§ˆ ģ»Øģ„¬ź²Œģ“ķŠø
EP1140157B1 (en) * 1998-12-21 2009-02-18 MedImmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
EP1880735A3 (en) 1999-03-19 2008-03-12 GlaxoSmithKline Biologicals S.A. Vaccine
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CN201252175Y (zh) * 2008-08-04 2009-06-03 åƌ士åŗ·(ę˜†å±±)ē”µč„‘ęŽ„ę’ä»¶ęœ‰é™å…¬åø ēŗæē¼†čæžęŽ„å™Øē»„件

Also Published As

Publication number Publication date
HU228499B1 (en) 2013-03-28
JP5551579B2 (ja) 2014-07-16
NO20014322L (no) 2001-11-14
EP1880735A3 (en) 2008-03-12
DE60032120T2 (de) 2007-09-20
HK1043730A1 (zh) 2002-09-27
EP1162998A2 (en) 2001-12-19
KR100798212B1 (ko) 2008-01-24
EP1880735A2 (en) 2008-01-23
WO2000056360A2 (en) 2000-09-28
HK1043728A1 (en) 2002-09-27
CZ303653B6 (cs) 2013-01-30
CN1191852C (zh) 2005-03-09
HUP0200367A2 (en) 2002-05-29
IL145044A0 (en) 2002-06-30
BE1025464I2 (enExample) 2019-03-06
FR10C0008I2 (fr) 2012-10-26
BRPI0009163B1 (pt) 2019-04-09
US20060002961A1 (en) 2006-01-05
PT1162999E (pt) 2007-02-28
TWI286938B (en) 2007-09-21
CY2009014I2 (el) 2010-07-28
ES2300255T3 (es) 2008-06-16
HUP0200664A2 (en) 2002-06-29
DK1163000T3 (da) 2008-04-28
AR022964A1 (es) 2002-09-04
AR022965A1 (es) 2002-09-04
IL145043A (en) 2007-06-17
JP2002540074A (ja) 2002-11-26
DE60043930D1 (de) 2010-04-15
ES2275499T3 (es) 2007-06-16
BR0009166A (pt) 2001-12-26
NZ513842A (en) 2004-05-28
KR20020000785A (ko) 2002-01-05
CY2009014I1 (el) 2010-07-28
CA2366314A1 (en) 2000-09-28
SI1162999T1 (sl) 2007-04-30
EP1776962A1 (en) 2007-04-25
HK1043728B (en) 2007-06-22
JP2002539273A (ja) 2002-11-19
EP1162999A2 (en) 2001-12-19
NO20014323L (no) 2001-11-14
US20150079125A1 (en) 2015-03-19
EP2277535A2 (en) 2011-01-26
DE60038166D1 (de) 2008-04-10
MY125202A (en) 2006-07-31
ES2339737T3 (es) 2010-05-25
AU750762B2 (en) 2002-07-25
CA2366152A1 (en) 2000-09-28
CN100339130C (zh) 2007-09-26
US20050031646A1 (en) 2005-02-10
CN1192798C (zh) 2005-03-16
NO20014325D0 (no) 2001-09-05
SI1163000T1 (sl) 2008-06-30
LU91652I9 (enExample) 2019-01-03
US20060093626A1 (en) 2006-05-04
HK1043731A1 (en) 2002-09-27
US20110217329A1 (en) 2011-09-08
MY125387A (en) 2006-07-31
DE60032120D1 (de) 2007-01-11
DK1162999T3 (da) 2007-03-26
EP1163000A2 (en) 2001-12-19
US20100119544A1 (en) 2010-05-13
US20030147922A1 (en) 2003-08-07
NZ513841A (en) 2001-09-28
US8926985B2 (en) 2015-01-06
CN1351501A (zh) 2002-05-29
KR20020001785A (ko) 2002-01-09
KR20020000549A (ko) 2002-01-05
CY1107390T1 (el) 2010-07-28
CZ20013379A3 (cs) 2002-03-13
MXPA01009452A (es) 2002-08-06
IL145043A0 (en) 2002-06-30
US9168313B2 (en) 2015-10-27
CN1351503A (zh) 2002-05-29
IL145045A0 (en) 2002-06-30
EP1162999B1 (en) 2006-11-29
NO2011014I2 (no) 2011-08-30
DE60038166T2 (de) 2009-03-12
EP2277535A3 (en) 2011-03-09
HUP0200373A2 (en) 2002-06-29
JP2011057713A (ja) 2011-03-24
FR10C0008I1 (fr) 2010-03-26
PL355180A1 (en) 2004-04-05
PL355178A1 (en) 2004-04-05
DE122009000054I1 (de) 2009-12-31
NL300415I1 (nl) 2009-12-01
NO20014323D0 (no) 2001-09-05
LU91652I2 (fr) 2010-10-13
CA2366314C (en) 2012-01-10
TR200102735T2 (tr) 2002-04-22
BR0009163A (pt) 2001-12-26
KR100642044B1 (ko) 2006-11-10
PL204890B1 (pl) 2010-02-26
CZ301445B6 (cs) 2010-03-03
TR200102736T2 (tr) 2002-04-22
CZ20013378A3 (cs) 2002-03-13
TR200102739T2 (tr) 2001-12-21
PT1163000E (pt) 2008-03-20
US20100291138A1 (en) 2010-11-18
HK1043731B (en) 2009-01-23
ATE387214T1 (de) 2008-03-15
WO2000056359A2 (en) 2000-09-28
EP1163000B1 (en) 2008-02-27
BRPI0009163B8 (pt) 2021-05-25
TWI281403B (en) 2007-05-21
PL203917B1 (pl) 2009-11-30
ATE346608T1 (de) 2006-12-15
WO2000056358A3 (en) 2001-01-04
NO20014325L (no) 2001-11-14
ATE459373T1 (de) 2010-03-15
CY1107561T1 (el) 2013-03-13
JP4846906B2 (ja) 2011-12-28
AU750913B2 (en) 2002-08-01
AU3430700A (en) 2000-10-09
WO2000056359A3 (en) 2001-02-01
CN1391481A (zh) 2003-01-15
PL355264A1 (en) 2004-04-05
NO330736B1 (no) 2011-06-27
NZ513840A (en) 2004-02-27
WO2000056358A2 (en) 2000-09-28
JP2002540075A (ja) 2002-11-26
AR022963A1 (es) 2002-09-04
AU3291900A (en) 2000-10-09
BR0009154A (pt) 2001-12-26
HU229968B1 (hu) 2015-03-30
AU750788B2 (en) 2002-07-25
HUS1500040I1 (hu) 2018-05-28
CA2365296A1 (en) 2000-09-28
NO2011014I1 (no) 2011-09-19
EP1162998B1 (en) 2010-03-03
NO330532B1 (no) 2011-05-09
TWI235064B (en) 2005-07-01
NO20014322D0 (no) 2001-09-05
WO2000056360A3 (en) 2001-01-25
AU3813600A (en) 2000-10-09
CZ20013380A3 (cs) 2002-03-13
IL145044A (en) 2007-03-08

Similar Documents

Publication Publication Date Title
BE2013C020I2 (enExample)
BE2013C015I2 (enExample)
BE2013C001I2 (enExample)
BE2012C036I2 (enExample)
BE1025464I2 (enExample)
BE2008C046I2 (enExample)
BE2010C011I2 (enExample)
JP2002514480A5 (enExample)
IN2001KO01233A (enExample)
JP2002521141A5 (enExample)
BE2008C047I2 (enExample)
BE2011C004I2 (enExample)
JP2002521591A5 (enExample)
JP2002517184A5 (enExample)
JP2002519925A5 (enExample)
JP2002513244A5 (enExample)
JP2002506962A5 (enExample)
JP2002521163A5 (enExample)
JP2002513606A5 (enExample)
JP2002502016A5 (enExample)
JP2002522346A5 (enExample)
HU0004772D0 (enExample)
FI4323U1 (enExample)
JP2001182743A5 (enExample)
IN188678B (enExample)